List of largest selling pharmaceutical products
Best selling pharmaceuticals of U.S. Market
The top 5 best selling pharmaceuticals 2015-2019. Sales in billion USD.[1]
| Rank | Drug | Main indication | Trade name | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|---|---|---|
| 1 | adalimumab | rheumatoid arthritis | Humira | 10.1 | 13.5 | 16.3 | 18.4 | 21.4 |
| 2 | apixaban | anticoagulant | Eliquis | 1.6 | 3.0 | 4.6 | 7.1 | 9.9 |
| 3 | etanercept | rheumatoid arthritis | Enbrel | 7.2 | 7.6 | 7.9 | 8.0 | 8.1 |
| 4 | ustekinumab | psoriasis | Stelara | 2.0 | 2.6 | 3.7 | 5.0 | 6.6 |
| 5 | pembrolizumab | oncology | Keytruda | 0.4 | 0.7 | 2.2 | 4.3 | 6.5 |
Best selling pharmaceuticals of 2017/18
The top 16 best selling pharmaceuticals of 2017/18.[2]
| Rank | Drug | Main indication | Trade name | 2018 sales (million USD) | 2017 sales (million USD) |
|---|---|---|---|---|---|
| 1 | adalimumab | rheumatoid arthritis | Humira | 19 936 | 18427 |
| 3 | apixaban | anticoagulant | Eliquis | 9872 | 7395 |
| 4 | lenalidomide | multiple myeloma | Revlimid | 9685 | 8187 |
| 5 | nivolumab | oncology | Opdivo | 7570 | 5763 |
| 6 | pembrolizumab | oncology | Keytruda | 7171 | 3809 |
| 7 | etanercept | rheumatoid arthritis | Enbrel | 7126 | 7885 |
| 8 | trastuzumab | breast cancer | Herceptin | 6981 | 7013 |
| 9 | bevacizumab | colon cancer | Avastin | 6847 | 6686 |
| 10 | rituximab | non-Hodgkin's lymphoma | Rituxan,
MabThera |
6750 | 7298 |
| 11 | rivaroxaban | anticoagulant | Xarelto | 6589 | 6234 |
| 12 | aflibercept | Eylea | 6551 | 5830 | |
| 13 | infliximab | Remicade | 5908 | 7152 | |
| 14 | Pneumococcal conjugate vaccine | Prevnar 13
Prevenar 13 |
5802 | 5601 | |
| 15 | ustekinumab | Stelara | 5156 | 4011 | |
| 16 | pregabalin | epilepsy | Lyrica | 4970 | 5065 |
Largest selling pharmaceutical products of 2015
Drugs with sales above $5 billion in 2015 included:[3]
| Rank | Drug | Trade name | Type | Main indications | Company | Sales (USD millions/year) | ∆ vs 2014 |
|---|---|---|---|---|---|---|---|
| 1 | Adalimumab | Humira | Biologic | Rheumatoid arthritis | AbbVie Inc. | 14,012 | 1,469 |
| 2 | Ledipasvir/sofosbuvir | Harvoni | Small molecule | Hepatitis C | Gilead Sciences | 13,864 | 11,737 |
| 3 | Etanercept | Enbrel | Biologic | Rheumatoid arthritis | Amgen | 8,697 | 4,009 |
| 4 | Infliximab | Remicade | Biologic | Crohn's Disease Rheumatoid Arthritis |
Johnson & Johnson | 8,355 | 1,487 |
| 5 | Rituximab | Mabthera
Rituxan |
Biologic | Lymphoma | Roche | 7,115 | 1,456 |
| 6 | Insulin glargine | Lantus | Biologic | Diabetes mellitus | Sanofi | 7,029 | 51 |
| 7 | Bevacizumab | Avastin | Biologic | Metastatic cancers | Roche | 6,751 | 270 |
| 8 | Trastuzumab | Herceptin | Biologic | Breast cancer | Roche | 6,603 | 265 |
| 9 | Lenalidomide | Revlimid | Small molecule | Multiple myeloma | Celgene | 5,801 | 821 |
| 10 | Sofosbuvir | Sovaldi | Small molecule | Hepatitis C | Gilead Sciences | 5,276 | (5,007) |
| 11 | Fluticasone propionate/salmeterol | Seretide
Advair |
Small molecule | Asthma | GlaxoSmithKline | 5,227 | (778) |
| 12 | Rosuvastatin | Crestor | Small molecule | Cardiovascular diseases | AstraZeneca | 5,017 | (495) |
Best selling pharmaceuticals of 2013
For the fourth quarter of 2013, the largest selling drugs were:[4]
| Rank | Brand Name(s) | Generic Name | Sales Q1 2014 Sales ($000) | Change from Q4 2013 | Company(ies) | Disease/Medical Use | First Approval Date | Patent Expiration Date[5][6] |
|---|---|---|---|---|---|---|---|---|
| 1 | Abilify | Aripiprazole | 1,602,329 | 2.23% | Generic | Psychosis; depression | Nov-2002 | 2014-Oct |
| 2 | Humira | Adalimumab | 1,561,861 | 3.86% | AbbVie | Crohn's disease; Rheumatoid arthritis | Dec-2002 | 2016-Dec |
| 3 | Nexium | Esomeprazole | 1,536,435 | 0.74% | Generic | Gastrointestinal disorders | Mar-2000 | 2014-May |
| 4 | Crestor | Rosuvastatin | 1,333,502 | 4.53% | AstraZeneca, Shionogi | Cholesterol | Nov-2002 | 2016-Jul |
| 5 | Enbrel | Etanercept | 1,189,844 | 1.46% | Amgen | Rheumatoid arthritis | Nov-1998 | 2012-Oct |
| 6 | Advair Diskus, Seretide | Fluticasone/salmeterol | 1,147,330 | 2.65% | GlaxoSmithKline | Asthma | Aug-2000 | 2012-Mar |
| 8 | Remicade | Infliximab | 994,020 | -2.71% | Centocor Ortho Biotech, Inc., Mitsubishi Tanabe Pharma | Crohn's disease; rheumatoid arthritis | Aug-1998 | n/a |
| 9 | Lantus Solostar | Insulin glargine | 939,691 | 9.39% | Sanofi-Aventis | Diabetes mellitus type 1 and 2 | Apr-2000 | 2011-Dec |
| 10 | Neulasta | Pegfilgrastim | 854,508 | -4.90% | Amgen | Neutropenia | Jan-2002 | Mon-20XX |
| 11 | Copaxone | Glatiramer | 851,351 | -4.69% | Generic | Multiple sclerosis | Dec-1996 | Nov-2014 |
| 12 | Rituxan, MabThera | Rituximab | 746,766 | -0.16% | Biogen Idec, Chugai Pharmaceutical, Genentech/Roche | Non-Hodgkin’s lymphoma; rheumatoid arthritis | Nov-1997 | Mon-20XX |
| 13 | Spiriva | Tiotropium bromide | 726,057 | 3.39% | Boehringer Ingelheim | Chronic obstructive pulmonary disease | Apr-2002 | 2018-Jul |
| 14 | Januvia | Sitagliptin | 700,941 | 3.63% | Merck & Co., Inc. | Diabetes mellitus type 2 | Dec-1996 | 2017-Nov |
| 15 | Lantus | Insulin glargine | 685,461 | 5.84% | Sanofi-Aventis | Diabetes mellitus type 1 and 2 | Apr-2000 | Dec-2011 |
| 16 | Atripla | Emtricitabine/tenofovir/efavirenz | 679,418 | 0.36% | Gilead Sciences, Inc. | HIV infection | Dec-1996 | Mar-2015 |
| 17 | Cymbalta | Duloxetine | 664,186 | -23.06% | Generic | Depression; anxiety disorders | Aug-2004 | Dec-2013 |
| 18 | Avastin | Bevacizumab | 650,208 | -1.25% | Genentech/Roche | Cancer | Feb-2004 | Mon-20XX |
| 19 | Lyrica | Pregabalin | 624,774 | 2.82% | Pfizer | Neuropathic pain | Jul-2004 | Jul-2019 |
| 20 | OxyContin | Oxycodone | 585,482 | -2.91% | Generic | Pain | Dec-1996 | Mon-20XX |
| 21 | Celebrex | Celecoxib | 580,332 | 5.23% | Generic | Osteoarthritis; rheumatoid arthritis | Dec-1998 | May-2014 |
| 22 | Epogen | Epoetin alfa | 503,493 | -2.08% | Amgen | Anemia | Jun-1989 | Mon-20XX |
| 23 | Truvada | Tenofovir/emtricitabine | 542,846 | 0.03% | Gilead Sciences | HIV infection | Aug-2004 | Mon-20XX |
| 24 | Diovan | Valsartan | 533,924 | -2.80% | Generic | Hypertension | Dec-1996 | Sep-2012 |
| 25 | Levemir | Insulin detemir | 424,186 | 9.34% | Novo Nordisk | Diabetes mellitus type 1 and 2 | Dec-1990 | Mon-20XX |
| 26 | Gleevec, Glivec | Imatinib | 498,149 | 7.22% | Novartis | Leukemia | May-2001 | Jan-2015 |
| 27 | Herceptin | Trastuzumab | 473,632 | 1.53% | Chugai Pharmaceutical, Genentech/Roche | Breast cancer | Sep-1998 | Mon-20XX |
| 28 | Vyvanse | Lisdexamfetamine | 447,188 | 9.39% | Shire | Attention deficit hyperactivity disorder | Dec-1990 | Mon-20XX |
| 29 | Lucentis | Ranibizumab | 460,621 | -0.84% | Genentech | Macular degeneration | Dec-1990 | Mon-20XX |
| 30 | Zetia | Ezetimibe | 444,731 | 4.04% | Merck & Co., Schering-Plough | Cholesterol | Oct-2002 | 2017-Oct |
| 31 | Combivent | Ipratropium bromide/salbutamol | 391,404 | 20.28% | Boehringer Ingelheim | Chronic obstructive pulmonary disease | Oct-1996 | Mon-20XX |
| 32 | Symbicort | Budesonide/formoterol | 407,646 | 9.63% | AstraZeneca | Asthma | Aug-2000 | Mon-20XX |
| 33 | Namenda | Memantine | 434,766 | -6.00% | Generic | Alzheimer's disease | Oct-2003 | Apr-2014 [9] |
| 34 | NovoLog FlexPen | Insulin aspart | 364,870 | 7.84% | Novo Nordisk | Diabetes mellitus type 1 and 2 | Oct-1996 | Mon-20XX |
| 35 | Xarelto | Rivaroxaban | 321,462 | 18.72% | Bayer | Oral anticoagulant | Dec-1996 | Sep-2012 |
| 36 | NovoLog | Insulin aspart | 344,235 | 3.86% | Novo Nordisk | Diabetes mellitus type 1 and 2 | Oct-1996 | Mon-20XX |
| 37 | Humalog | Insulin lispro | 304,866 | 6.15% | Eli Lilly and Company | Diabetes mellitus type 1 and 2 | Apr-1996 | Mon-20XX |
| 38 | Suboxone | Buprenorphine | 321,892 | -2.11% | Reckitt Benckiser Pharmaceuticals Inc. | Pain; opioid addiction | Aug-2000 | Mon-20XX |
| 40 | Viagra | Sildenafil | 300,463 | 3.26% | Pfizer | Erectile dysfunction | Mar-1998 | Mar-2012 |
| 41 | Seroquel XR | Quetiapine | 291,494 | 2.22% | Generic | Psychosis; depression | Sep-1997 | Mar-2012 |
| 33 | Incivo | Telaprevir | 370,899 | 0.00% | Johnson & Johnson | Hepatitis C | Dec-1990 | Mon-20XX |
| 35 | AndroGel | Testosterone gel | 351,737 | 5.47% | Generic | Low testosterone levels | Oct-2002 | Oct-2016 |
| 37 | Enoxaparin | Enoxaparin | 341,184 | 6.55% | Generic | Deep-vein thrombosis | Mar-1993 | 2012-Aug |
| 38 | Ritalin | Methylphenidate | 327,346 | 2.26% | Generic | Attention deficit hyperactivity disorder | Aug-2000 | Mon-20XX |
| 41 | ProAir HFA | Salbutamol | 306,461 | 10.87% | Teva Pharmaceuticals | Asthma; chronic obstructive pulmonary disease | Oct-1996 | Mon-20XX |
| 43 | Alimta | Pemetrexed | 302,728 | 6.00% | Eli Lilly and Company | Cancer | Feb-2004 | Mon-20XX |
| 44 | Victoza | Liraglutide | 301,414 | 9.59% | Novo Nordisk | Diabetes mellitus type 2 | May-1909 | Mon-20XX |
| 47 | Synagis | Palivizumab | 289,704 | 0.00% | MedImmune | RSV infection | Feb-1998 | Aug-2012 |
| 48 | Avonex | Interferon beta 1a | 281,554 | -1.43% | Biogen Idec | Multiple sclerosis | May-1996 | Mon-20XX |
| 49 | Renvela | Sevelamer | 280,917 | 21.44% | Generic | Hyperphosphatemia | Apr-2002 | Apr-2016 [10] |
| 50 | Rebif | Interferon beta 1a | 280,548 | -6.27% | Serono | Multiple sclerosis | Feb-1998 | Mon-20XX |
| 51 | Cialis | Tadalafil | 280,518 | 4.58% | Eli Lilly and Company, Lilly Icos | Erectile dysfunction | Nov-2002 | 2017-Nov |
| 52 | Gilenya | fingolimod | 272,701 | 4.05% | Novartis Corporation | Multiple sclerosis | Feb-2000 | 2007-Jan |
| 53 | Nasonex | Mometasone | 272,345 | 5.67% | Schering-Plough | Allergic rhinitis | Oct-1997 | 2018-Oct |
| 54 | Stelara | Ustekinumab | 270,598 | 12.47% | Johnson & Johnson | Psoriasis; psoriatic arthritis | Apr-2000 | Mon-20XX |
| 55 | Restasis | Ciclosporin ophthalmic emulsion | 268,463 | 6.30% | Allergan, Inc, Lilly Icos | Dry eye syndrome | Nov-2002 | Mon-20XX |
| 56 | Budesonide | Budesonide | 268,201 | 26.81% | Generic | Asthma | Aug-2000 | Mon-20XX |
| 57 | Acetaminophen/hydrocodone | Acetaminophen/hydrocodone | 264,814 | 6.67% | Generic | Pain | Aug-2000 | Mon-20XX |
| 58 | Flovent HFA | Fluticasone propionate | 263,072 | 13.97% | GlaxoSmithKline | Asthma | Mar-1996 | Mon-20XX |
| 59 | Lovaza | Omega-3 fatty acid ethyl esters | 258,177 | 2.90% | GlaxoSmithKline | Cholesterol | Jun-2001 | Mon-20XX |
| 60 | Prezista | Darunavir | 251,372 | 3.54% | Johnson & Johnson | HIV infection | Jun-2006 | Mon-20XX |
| 61 | Isentress | Raltegravir | 248,924 | 0.72% | Merck & Co., Inc. | HIV Infection | Dec-1998 | Mon-20XX |
| 62 | Janumet | Sitagliptin/metformin | 247,150 | 4.65% | Merck & Co., Inc. | Diabetes mellitus type 2 | Dec-1998 | Mon-20XX |
| 63 | Procrit, Eprex | Epoetin alfa | 241,535 | -10.09% | Johnson & Johnson | Anemia | Dec-1990 | Mon-20XX |
| 64 | Doxycycline | Doxycycline | 241,381 | -5.65% | Generic | Bacterial infections | Dec-1996 | Nov-2011 |
| 65 | Orencia | Abatacept | 241,149 | 1.65% | Bristol-Myers Squibb Company | Rheumatoid arthritis | Aug-2000 | Mon-20XX |
| 66 | Amphetamine/dextroamphetamine | Amphetamine mixed salts | 240,482 | 2.78% | Generic | Attention deficit hyperactivity disorder; narcolepsy | Feb-2004 | Mon-20XX |
| 67 | Vesicare | Solifenacin | 240,435 | 5.37% | Astellas Pharma US | Overactive bladder | Feb-2000 | 2018-Nov |
| 68 | Dexilant | Dexlansoprazole | 238,897 | 7.57% | Takeda Pharmaceuticals North America, Inc | Gastrointestinal disorders | Dec-2004 | Jul-2012 |
| 69 | Humalog KwikPen | Insulin lispro | 238,418 | 11.02% | Eli Lilly and Company | Diabetes mellitus type 1 and 2 | Apr-1996 | Mon-20XX |
| 70 | Neupogen | Filgrastim | 229,912 | -2.70% | Amgen | Neutropenia | Feb-1991 | Mon-20XX |
| 71 | Lidocaine | Lidocaine | 225,903 | 0.00% | Generic | Pain | Mar-1999 | Mon-20XX |
| 72 | Lunesta | Eszopiclone | 225,101 | 5.24% | Generic | Insomnia | Dec-2004 | April-2015 |
| 73 | Fenofibrate | Fenofibrate | 223,300 | -2.22% | Generic | Cholesterol | Feb-1998 | Mon-20XX |
| 74 | Zytiga | Abiraterone | 222,026 | 11.86% | Janssen Biotech, Inc. | Prostate Cancer | Dec-1998 | April-2015 |
| 75 | Reyataz | Atazanavir | 217,793 | -1.38% | Bristol-Myers Squibb | HIV infection | Jan-2003 | Mon-20XX |
| 76 | Sensipar | Cinacalcet | 216,657 | 13.71% | Amgen Inc. | Hyperparathyroidism | Apr-2000 | Mon-20XX |
| 77 | Metoprolol | Metoprolol | 215,111 | 2.99% | Generic | Hypertension | Jan-1992 | Mon-20XX |
| 78 | AcipHex | Rabeprazole | 214,251 | 10.03% | Janssen Pharmaceuticals, Inc, Johnson & Johnson | Gastrointestinal disorders | Aug-1999 | Nov-2013 |
| 79 | Synthroid | Levothyroxine | 213,424 | -2.50% | Generic | Hypothyroidism | May-1999 | Expired |
| 80 | Avonex Pen | Olmesartan | 211,917 | 13.59% | Biogen Idec, Forest Laboratories | Hypertension | Apr-2002 | Apr-2016 |
| 81 | Prevnar 13 | Pneumococcal conjugate vaccine | 209,367 | 6.41% | Pfizer | Pneumococcal disease | Feb-2000 | Jan-2007 |
| 82 | Xolair | Omalizumab | 207,891 | 1.91% | Genentech, Novartis | Asthma | 2003 | Mon-20XX |
| 83 | Lipitor | Atorvastatin | 207,542 | 4.23% | Generic | Cholesterol | Dec-1996 | Nov-2011 [12] |
| 84 | levothyroxine | Levothyroxine | 204,755 | 0.00% | Generic | Hypothyroidism | Aug-1990 | Mon-20XX |
| 85 | Benicar | Olmesartan/hydrochlorothiazide | 203,336 | 3.22% | Daiichi Sankyo | Hypertension | Jun-1909 | Mon-2016 |
| 86 | Stribild | Elvitegravir/cobicistat/emtricitabine/tenofovir | 202,642 | 0.00% | Gilead Sciences | HIV/AIDS | Apr-2000 | Mon-20XX[13] |
| 87 | Zostavax | Zostavax | 202,240 | 15.17% | Eisai, Merck & Co. | Herpes zoster | Aug-1999 | May-2013 |
| 88 | Pradaxa | Dabigatran | 200,697 | -0.53% | Boehringer Ingelheim, Lilly Icos | Oral anticoagulant | Oct-2010 | Mon-20XX |
| 89 | Vytorin | Ezetimibe/simvastatin | 199,625 | -3.02% | Merck & Co., Schering-Plough | Cholesterol | Jul-2004 | Mon-20XX |
| 90 | Tamiflu | Oseltamivir | 197,718 | 0.00% | Chugai Pharmaceutical, Hetero Drugs, Roche | Influenza | Oct-1999 | Mon-20XX |
| 91 | Xgeva | Denosumab | 197,711 | 3.24% | Amgen | Osteoporosis | Nov-2010 | Mon-20XX |
| 92 | Evista | Raloxifene | 196,929 | -4.31% | Eli Lilly and Company, Chugai Pharmaceutical | Osteoporosis | Dec-1997 | Jan-2013 |
| 93 | Xeloda | Capecitabine | 194,044 | 6.52% | Generic | Cancer | Jun-1909 | Mon-20XX [14] |
| 94 | Aranesp | Darbepoetin alfa | 185,225 | -9.22% | Amgen Inc. | Anemia | Jun-2001 | Mon-20XX |
| 95 | Ventolin HFA | Salbutamol | 183,060 | 0.00% | GlaxoSmithKline | Asthma; chronic obstructive pulmonary disease | May-1981 | Mon-20XX |
| 96 | divalproex sodium | Valproate | 181,554 | 0.00% | Generic | Epilepsy and bipolar disorder [15] | Jun-1909 | Mon-20XX |
| 97 | Afinitor | Everolimus | 180,719 | 0.03% | Novartis | Cancer | Jun-1909 | Mon-20XX |
| 98 | Betaseron, Betaferon | Interferon beta 1b | 179,216 | -3.72% | Bayer | Multiple sclerosis | Jul-1993 | Mon-20XX |
| 99 | Adderall XR | Amphetamine mixed salts | 177,505 | 3.31% | Generic | Attention deficit hyperactivity disorder | Oct-2001 | Mon-20XX |
| 100 | Complera | Emtricitabine/Rilpivirine/Tenofovir disoproxil fumarate | 174,933 | 0.00% | Gilead Sciences, Inc. | HIV | Jun-20XX | Mon-20XX |
See also
- List of drugs
- Lists about the pharmaceutical industry
References
- "Medicine Spending and Affordability in the United States: Understanding Patients' Costs for Medicines". IQVIA Institute for Human Data Science. Archived from the original on 17 Sep 2020.
- "Top 15 Best-Selling Drugs of 2018". GEN - Genetic Engineering and Biotechnology News. 2019-03-11. Retrieved 2019-05-30.
- "Top drugs by sales revenue in 2015: Who sold the biggest blockbuster drugs?". March 10, 2016. Retrieved October 19, 2016.
- Drugs.com U.S. Pharmaceutical Sales - Q4 2013, updated Feb. 2014
- Patent Terms Extended Under 35 USC §156
- Orange Book Trade Name Search
- https://www.drugs.com/availability/generic-oxycontin.html. Missing or empty
|title=(help) - https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm399428.htm. Missing or empty
|title=(help) - Unknown. "Generic Namenda Availability - Drugs.com". www.drugs.com. Drugs.com. Retrieved 21 December 2015.
- Donohue, Mark. "Impax Laboratories Inc. - Impax Launches Authorized Generic RENVELA®". investors.impaxlabs.com. Impax Laboratories. Retrieved 21 December 2015.
- Armstrong, Drew; Decker, Susan. "Pfizer's blockbuster blue pill Viagra set to go generic in 2015". Indianapolis Star. Retrieved 25 December 2015.
- "Atorvastatin: Drug Uses, Dosage, Side Effects - Drugs.com". www.drugs.com. drugs.com. Retrieved 21 December 2015.
- "HIV Treatment". www.stribild.com.
- Walsh, Sandy. "Press Announcements - FDA approves first generic capecitabine to treat colorectal and breast cancers". www.fda.gov. United States Food and Drug Administration. Retrieved 21 December 2015.
- "Valproic Acid". The American Society of Health-System Pharmacists. Archived from the original on 2017-07-31. Retrieved Oct 23, 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.